Compass Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q2 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Compass Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2018 to Q3 2024.
  • Compass Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$12.2M, a 2.63% decline year-over-year.
  • Compass Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$55.4M, a 15.8% decline year-over-year.
  • Compass Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$50.4M, a 20.9% decline from 2022.
  • Compass Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$41.7M, a 49.1% increase from 2021.
  • Compass Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$81.9M, a 194% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$55.4M -$12.2M -$313K -2.63% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$55.1M -$15M -$1.71M -12.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 -$53.4M -$12.8M -$3.06M -31.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$50.4M -$15.4M -$2.5M -19.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$47.9M -$11.9M +$672K +5.33% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$48.5M -$13.3M -$4.35M -48.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 -$44.2M -$9.71M -$2.53M -35.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$41.7M -$12.9M +$112K +0.86% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$41.8M -$12.6M -$6.74M -115% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$35M -$8.99M +$46.7M +83.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$81.7M -$7.18M +$157K +2.14% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$81.9M -$13M -$5.05M -63.5% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 -$76.8M -$5.85M +$3.11M +34.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$79.9M -$55.7M -$50.6M -998% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-01
Q1 2021 -$29.3M -$7.34M -$1.51M -25.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$27.8M -$7.95M +$2.29M +22.3% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-18
Q3 2020 -$30.1M -$8.96M -$578K -6.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$29.5M -$5.07M +$3.6M +41.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$33.1M -$5.83M -$30.7M -123% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 -$2.38M -$10.2M -$971K -10.5% Oct 1, 2019 Dec 31, 2019 10-Q 2020-02-14
Q3 2019 -$1.41M -$8.38M -$598K -7.68% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$812K -$8.67M -$779K -9.87% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$32.8K $24.9M Jan 1, 2019 Mar 31, 2019 10-K 2020-06-08
Q4 2018 -$9.27M Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
Q3 2018 -$7.79M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$7.89M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.